Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? (Q38343383)

2 September 2017

1 reference

title

Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis? (English)

1 reference

invasive ductal carcinoma

2 September 2017

main subject

1 reference

pancreatic ductal adenocarcinoma

inferred from title

1 reference

pancreatic ductal carcinoma

inferred from title

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Toshihiko Torigoe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Yoshihiko Hirohashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Noriyuki Sato

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Goro Kutomi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Yasutoshi Kimura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Toru Mizuguchi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Toshihiko Nishidate

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Kenji Okita

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Fukino Satomi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Masayuki Ishii

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Makoto Meguro

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Hiroaki Shima

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Shigenori Ota

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Hiroshi Hayashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Sumiyo Asakura

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Masaho Ishino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Atsushi Miyamoto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Koichi Hirata

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

5 February 2015

1 reference

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

139-148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Vaccine therapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Vaccines for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

What is recent in pancreatic cancer immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Novel insights into the molecular mechanisms of HLA class I abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Immunobiotherapy directed against mutated and aberrantly expressed gene products in pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Immortal activated human hepatic stellate cells generated by ectopic telomerase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

An international multicenter randomized controlled trial of G17DT in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Immunotherapy of human cancer: lessons from mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Immunotherapy for pancreatic cancer - science driving clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Listeria-based cancer vaccines that segregate immunogenicity from toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Immunohistochemistry of CEA in the human pancreas during development, in the adult, chronic pancreatitis, and pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

A clinical development paradigm for cancer vaccines and related biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Cancer vaccines. Any future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00595-015-1120-8

Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer

21 January 2018

1 reference

12 December 2020

Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients

1 reference

12 December 2020

A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients

1 reference

12 December 2020

Controversies in the adjuvant treatment of pancreatic adenocarcinoma

1 reference

12 December 2020

An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.

1 reference

12 December 2020

IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs

1 reference

12 December 2020

MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer

1 reference

12 December 2020

Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell

1 reference

12 December 2020

Portal vein infusion chemotherapy with gemcitabine after surgery for pancreatic cancer

1 reference

12 December 2020

A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer

1 reference

12 December 2020

G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy

1 reference

12 December 2020

Identification of gastrin as a growth peptide in human pancreatic cancer

1 reference

12 December 2020

Telomerase activity in human solid tumors. Diagnostic utility and clinical applications.

1 reference

12 December 2020

Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis

1 reference

12 December 2020

A triad of costimulatory molecules synergize to amplify T-cell activation

1 reference

12 December 2020

A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients

1 reference

12 December 2020

Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.

1 reference

12 December 2020

Novel agents for the treatment of pancreatic cancer

1 reference

12 December 2020

A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma

1 reference

12 December 2020

10.1007/S00595-015-1120-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25649538%20AND%20SRC:MED&resulttype=core&format=json